Q-omics provides the consensus-scored CBY2 profile across patient tissues and cancer cell-line models. CBY2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CBY2 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CBY2 RNA expression shows 9,510 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, COAD, and THYM as cancer lineages where CBY2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBY2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBY2 survival associations across molecular data types. CBY2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBY2 RNA expression–survival associations across cancer types. High CBY2 expression shows unfavorable associations in LIHC, HNSC, KIRC, ACC and PCPG, but favorable associations in THCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CBY2 RNA expression.
This table summarizes CBY2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CBY2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBY2 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, STAD, LUSC and LUAD. The COAD box plot shows higher CBY2 RNA expression in tumor versus normal tissue (log2 FC = +1.545, t-test p < 0.001).
This table shows molecular features associated with CBY2 in patient tissues and cancer cell lines. In patient samples, CBY2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CBY2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
